1.Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T , Xie Z, Chu X, Yang J, Wang H, Chang Sh, Gong Y, Ruan L, Zhang G , Yan S, Lian W , Du C , Yang D , Zhang Q , Lin F, Liu J, Zhang H, Ge Ch, Xiao Sh, Ding J, Geng M*. Sodium Oligomannate Therapeutically Remodels Gut Microbiota and Suppresses Gut Bacterial Amino Acids-Shaped Neuroinflammation to Inhibit Alzheimer's Disease Progression. Cell Res,2019; 29 (10), 787-803.

2.Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A*, Ding J*, Geng M*. Identification and therapeutic intervention of coactivated anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type‐A receptor 5 kinases in hepatocellular carcinoma. Hepatology. 2019;69:573-586.

3.Huang X , Yan J, Zhang M , Wang Y, Chen Y, Fu X, Wei R, Zheng X， Liu Zh, Zhang X; Yang H，Hao B, Shen Y, Su Y, Cong X, Huang M, Tan M*, Ding J*, Geng M*.Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors, Cell, 2018;175(1):186-199.

4.Lian Q, Xu J, Yan S, Huang M*, Ding H, Sun X, Ding J*, Sun B* and Geng M*. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res 2017;27(6):784-800.

5.Yue X, Ai J, Xu Y, Chen Y, Huang M, Yang X, Hu B, Zhang H, He Ch, Yang X, Tang W, Peng X, Dong L, Wang H, Fan J*, Ding J*, Geng M*. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology. 2017;65(6):1948-1962.

6.Chen Y, Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y , Geng M*, and Ding J*. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin . Nature Commun. 2017 8(1):27.

7.Liu H, Ai J, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M*, Ding J*, Geng M*.c-Myc alteration determines the therapeutic response to FGFR inhibitors. Clin Cancer Res. 2017; 23(4):974-984.

8.Zeng H, Qu J, Jin N, Xu J, Lin C, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M*, Ding J*, Geng M*.Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. Cancer Cell, 2016;30(3):459-73.

9.Shen A, Wang L, Huang M, Sun J, Chen Y, Shen Y, Yang X, Wang X, Ding J*, Geng M*. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res, 2015 ,75(21):4548-59.

10.Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, Chen Y, Gao X, Zhu Q, Yue Xihua, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop Jennifer, He Y, Xu H.Eric, Fan J*, Ding J*, Geng M*. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. J Natl Cancer Inst. 103(22):1696-712, 2011